1. Home
  2. PHAR vs CBL Comparison

PHAR vs CBL Comparison

Compare PHAR & CBL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pharming Group N.V.

PHAR

Pharming Group N.V.

HOLD

Current Price

$17.78

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Logo CBL & Associates Properties Inc.

CBL

CBL & Associates Properties Inc.

HOLD

Current Price

$38.20

Market Cap

1.1B

Sector

Real Estate

ML Signal

HOLD

Company Overview

Basic Information
Metric
PHAR
CBL
Founded
1988
1978
Country
Netherlands
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Real Estate Investment Trusts
Sector
Health Care
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.1B
IPO Year
N/A
1993

Fundamental Metrics

Financial Performance
Metric
PHAR
CBL
Price
$17.78
$38.20
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
1
Target Price
$38.00
$45.00
AVG Volume (30 Days)
27.2K
161.7K
Earning Date
11-06-2025
02-13-2026
Dividend Yield
N/A
4.83%
EPS Growth
N/A
297.30
EPS
0.00
4.02
Revenue
$362,274,000.00
$553,643,000.00
Revenue This Year
$25.19
N/A
Revenue Next Year
$4.47
N/A
P/E Ratio
$3,085.37
$9.28
Revenue Growth
26.78
5.74
52 Week Low
$7.50
$21.10
52 Week High
$18.30
$38.67

Technical Indicators

Market Signals
Indicator
PHAR
CBL
Relative Strength Index (RSI) 55.36 65.85
Support Level $16.55 $37.19
Resistance Level $17.37 $38.09
Average True Range (ATR) 0.67 0.73
MACD -0.05 -0.12
Stochastic Oscillator 68.64 76.08

Price Performance

Historical Comparison
PHAR
CBL

About PHAR Pharming Group N.V.

Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.

About CBL CBL & Associates Properties Inc.

CBL & Associates Properties Inc is a real estate investment trust. The company engages in the ownership, development, acquisition, leasing, management and operation of regional shopping malls, outlet centers, lifestyle centers, open-air centers and other properties. CBL's sales predominantly derive from leasing arrangements with retail tenants. The company also generates revenue from management and development fees, as well as sales of its real estate assets. CBL expands its portfolio of assets through activities such as redevelopment, renovation, and expansion.

Share on Social Networks: